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Abstract
Background: If children with community-acquired pneumonia (CAP) do not recover within 48 hours after starting
antibiotic therapy, complications are possible and a checkup must be ensured.
Aim of the present study was to evaluate the improvement of pediatric CAP, within 48 hours after starting therapy,
in relation to age, etiology, clinical/laboratory characteristics and selected antibiotics.
Methods: Ninety-four children were treated for radiologically confirmed CAP, 64 by oral amoxicillin, 23 by
intravenous ampicillin and 7 by other antibiotics. The etiology of CAP was studied by serology, data on more than
20 clinical characteristics were collected retrospectively, and antibiotics were selected on clinical grounds.
Results: After starting of antibiotics, the mean duration of fever was higher in children ≥5 than <2 or 2-4 years of
age (p = 0.003). Fever continued >48 hours in 4 (4.3%) children and 2 additional children had empyema. Clinical,
radiological and laboratory characteristics and serological findings were not significantly associated with the
duration of fever. Fever continued >24 hours in 1 (4.8%) child treated with ampicillin and in 2 (8%) inpatients
compared with 19 (28.8%) children treated with amoxicillin (p = 0.007) and 23 (33%) outpatients (p = 0.0012),
respectively.
Conclusions: Respiratory rate and erythrocyte sedimentation rates were associated with rapid decrease of fever.
Anyway, none of the reported characteristics was able to predict treatment failures or delayed fever decrease in
children suffering from CAP.
Background
Streptococcus pneumoniae is the most common bacterial
agent in pediatric community-acquired pneumonia
( C A P )a ta n ya g e ,w h i l eMycoplasma pneumoniae is
more common among patients over 5 years of age [1].
The majority, over 90%, of basically healthy, western
children with CAP clinically improve with disappearance
of fever and reduction of breathing work within 48
hours after the onset of antibiotics, with no significant
differences between beta-lactames and macrolides as
first-line antibiotics [2-4]. In recent years, pneumococcal
macrolide resistance has become an emerging problem
[1], and complications such as empyema and even
necrotizing pneumonia have become more common
than earlier, particularly complicating pneumococcal
pneumonia [5-7]. Therefore, most international and
national guidelines recommend penicillin, amoxicillin or
other beta-lactames as first antibiotic choice for all chil-
dren with CAP at <5 years of age, and also in older chil-
dren if clinical signs and symptoms suggest
pneumococcal etiology [1]. The “48 hours rule” has
been included in most guidelines [8]: if symptoms and
signs of pneumonia have not started to improve within
48 hours after the beginning of antibiotic therapy, the
child must be re-evaluated and treatment must be chan-
ged if indicated.
We have recently published our results on the etiology
of infection (determined by serological means), [9-11]
the severity of illness (assessed by serum procalcitonin
and need of hospital care) [12] and the value of clinical
features [13] in differentiating between viral, pneumo-
coccal and atypical bacterial infections in 101 children
with CAP confirmed by radiology. In the present paper
we report the outcome of these children, in relation to
age, etiology, clinical characteristics and first-line anti-
biotics, with special focus on the improvement within
48 hours after starting therapy.
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Study subjects
During a surveillance period of 15 months in 2001-2002,
101 consecutive, previously healthy children with signs
and/or symptoms compatible with respiratory infection
(fever ≥37°C, tachypnea, cough and/or findings of
crackles, bronchial breathing or silenced sounds on aus-
cultation) and radiological infiltrations consistent with
p n e u m o n i aw e r ee l i g i b l ef o rt h es t u d ya tt h eD e p a r t -
ment of Paediatrics, University Hospital of Udine, Italy
[9-13]. The exclusion criteria were the neonatal age,
chronic infectious and non-infectious underlying dis-
eases, wheezing on auscultation and hospital-acquired
pneumonia [9]. The study was approved by the Ethics
Committee of the University of Udine, School of Medi-
cine, and an informed oral consent was obtained from
the parents of all children. The time between the begin-
ning of antibiotic therapy and the stable disappearance
of fever, always accompanied by a substantial clinical
improvement, was estimated from the fever curves of
the patient records for inpatients, or by asking the out-
patients’ parents at the pediatrician’s visit or by phone
48-72 hours after the diagnosis. In particular, the body
temperature was taken in hospitalized patients by the
nurses every six hours a day, while the outpatients’ par-
ents were specifically required to take and write the
body temperature down, at home, at least twice a day,
after a brief training in body temperature measuring
received by the nurses at the time of diagnosis. In both
in- and out-patients the body temperature was taken on
the axillary level, by means of standard mercury thermo-
meters, that were supplied to the outpatients’ parents by
the investigators. The body temperature data were avail-
able in 94/101 (93%) children, and they formed the sub-
jects of the present study: their mean age was 4.7 years
(range 0.3-14.7 years).
Etiological studies
Streptococcus pneumoniae etiology of CAP was diag-
nosed by significant increases of IgG antibodies to pneu-
mococcal pneumolysin or C-polysaccharide between
paired sera, using enzyme immunoassay (EIA). Non-cap-
sulated Haemophilus influenzae and Moraxella catar-
rhalis infections were diagnosed by significant increases
of IgG antibodies to whole cell antigens using EIA; all
cases were mixed infections with viruses or other bac-
teria. Mycoplasma pneumoniae etiology was diagnosed
by significant increases of antibodies in either comple-
ment fixation (CF) or EIA serology. Correspondingly,
Chlamydia pneumoniae etiology was diagnosed by EIA
and/or by micro immunofluorescence (MIF) [9], and
Simkania negevensis etiology by MIF [10]. Viral involve-
ment by respiratory syncytial virus (RSV), human
metapneumovirus (hMPV), influenza A and B virus,
parainfluenza 1, 2 and 3 virus, adenovirus and cytome-
galovirus was studied by EIA in paired sera [9,11].
Laboratory and radiological studies
On admission, C-reactive protein (CRP) and procalcito-
nin (PCT) were measured in serum samples, white
blood cells (WBC) and erythrocyte sedimentation rates
(ESR) in blood samples, as described previously [12]. In
2005, three experienced radiologists interpreted the
chest radiographs, and the infiltration was considered as
alveolar in 63 cases and as interstitial in 38 cases [12].
Pleural fluid was present in 14 cases.
Clinical definitions
Medical history and clinical characteristics were regis-
tered in the hospital records of the patients on admis-
sion by the medical doctors on duty. In 2006, one of the
authors (MD) collected data on over 20 items from
these records using a structured case record form,
including age, gender, fever on admission, respiratory
rate on admission, preceding and presenting clinical
signs and symptoms, and findings on physical examina-
tion. “Tachypnoea” was defined by the World Health
Organization criteria, that are respiratory rate >60
breaths/minute in children aged <2 months, >50
breaths/minute in children aged 2-12 months and >40
breaths/minute in children aged >12 months [14].
“Length of fever” was defined as the period in which a
patient became spontaneously (without the use of anti-
pyretic) and steadily non-feverish: the hours elapsed
from the time of CAP diagnosis to the time a body tem-
perature >37°C was last recorded. “Delayed recovery”
was defined as the combination of those patients with
fever for longer than 48 hours and/or those patients
who developed a complication, such as pleural empyema
or lung abscess [8].
Pharmacological choices
According to the policy of the hospital, all children with
pneumonia diagnosed by chest radiography were treated
with antibiotics, and the preferred drugs were amoxicil-
lin for oral therapy and ampicillin for intravenous ther-
apy. Other antibiotics were chosen by the doctors on
duty only by specific indications (cephalosporins in case
of penicillin allergy, macrolides in case of high suspicion
of atypical etiology). Oral amoxicillin was started for 55
children, oral amoxicillin-clavulanic acid for 4 children,
intravenous ampicillin for 21 children, oral cephalos-
porin (cephalexin) for 2 children, intravenous cephalos-
porin (ceftriaxone) for 6 children, and oral macrolides
for 4 children. Vancomycin was started in one and qui-
nolones in no case. In both in- and out-patients, the
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making so easy the record of the starting time of such
therapy.
Acetaminophen, iboprufen or ketoprofen were allowed
a n dt h e yw e r et h em o s tc o m m o n l yp r e s c r i b e da n t i p y r e -
tic and analgesic drugs in case of high fever or pain,
such as headache, chest pain, arthralgia, referred abdom-
inal pain [8].
Statistical analysis
In univariate statistical analyses, Fisher’se x a c tt e s tw a s
used for discrete variables and analysis of variance for
continuous variables. In multivariate analyses, adjusted
for age, linear regression was used for continuous vari-
ables and stratified analyses with Mantel-Haenzel chi
square tests for discrete variables.
Results
Forty-eight patients (51%) were enrolled during the win-
ter season, from December to March. Seventeen patients
were <24 months old, 41 were 2 to 4 years old and 36
were ≥5 years old. Twenty-five children were treated in
hospital, and their mean hospitalization time was 5.0
days (range 3-13 days). Bacterial infection was diagnosed
in 45 patients; S. pneumoniae was found in 17, M. pneu-
moniae in 25, C. pneumoniae in 8 and S. negevensis in 5
cases (9 were dual bacterial infections). Viral infection
was diagnosed in 38 children, including 15 RSV cases
and 5 hMPV cases; 19 were viral infections alone and
19 were mixed infections with typical or atypical
bacteria.
After starting of antibiotics, the mean ± SD duration
of fever was 23.0 ± 19.2 hours, being 15.6 ± 13.4 in <2
years, 18.9 ± 14.9 in 2-4 years and 31.2 ± 23.1 hours in
≥5 years old children (p = 0.003). Fever decreased in 44
(47%) children within 12 hours, in 25 (27%) between 13-
24 hours, in 21 (22%) between 25-48 hours, and in only
4 (4%) children after 48 hours. Fever continued for >24
hours in 10/58 (14.7%) children aged <5 years compared
with 15/36 (41.7%) children aged ≥5 years (p = 0.0154).
No clinical sign or symptom showed any significant
association with the duration of fever (Table 1). The
doctors assessed 37 patients as “ill-looking” on admis-
sion, 19 (51.4%) of which were treated with parenteral
antibiotics, that was used in 9 (15.8%) of the 57 “well-
looking” patients. From the 37 “ill-looking” patients,
only 2 (5.4%) had fever >24 hours vs. 23/57 (40.4%) of
“well-looking” children (p = 0.001). In both groups, S.
pneumoniae was found in 19% of the cases. Likewise, no
finding in physical or radiological examination asso-
ciated with the duration of fever, except for respiratory
rate that was associated with rapid, not with delayed
fever abatement (Table 1). Elevated ESR was associated
with rapid decrease of fever. A similar tendency was
seen also for elevated CRP, PCT and WBC, but the
results did not reach statistical significance (Table 1).
Ninety-four patients with adequate data available were
classified into 4 microbiological groups. The pneumo-
coccal group consisted of all 18 cases with S. pneumo-
niae etiology (including cases with viral and
mycoplasmal co-infection). The atypical bacterial group
consisted of 27 cases with M .p n e u m o n i a e ,C .p n e u m o -
niae or S. negevensis etiology (including cases with viral
co-infection; pneumococcal co-infections excluded). The
viral group consisted of 19 viral cases with no pneumo-
coccal or atypical bacterial co-infections, and the
30 cases with no serological findings formed the group
of unknown etiology. The serological classification of
CAP had no association with the duration of fever, and
the result remained negative also in multivariate
adjusted analysis (data not shown). Oral amoxicillin was
started for 11 patients (61%) of the pneumoccal group,
16 patients (59%) of the atypical bacterial group and
19 patients (63%) of the viral group.
Intravenous ampicillin was more effective than oral
amoxicillin or macrolide (Table 2); fever continued >24
hours in only 1 (4.8%), compared with 19 (28.8%)
patients treated with amoxicillin (p = 0.007) or with
those 2 (50.0%) treated with macrolide (p = 0.056). In
multivariate analyses, adjusted for age category, fever
lasted in mean 11.1 hours less in children treated with
ampicillin, than in those treated with amoxicillin (p =
0.001). The treatment setting was significantly associated
with the duration of fever (Table 2). In hospitalized chil-
dren the duration of fever was shorter than in outpati-
ents; the difference was significant also in the age-
adjusted analyses.
Finally, there were 6 patients with delayed recovery;
fever continued >48 hours in four >7-year-old children,
and two 3-year-old girls were treated for empyema for
>2 weeks in hospital (Table 3). On admission, four
of these 6 children were “looking ill”,a n dC R Pw a s
>80 mg/L in all cases. The other clinical and laboratory
findings varied a lot on admission. When the 2 children
with empyema and the only child with lung abscess
were excluded from the analyses, the mean duration of
antibiotic treatment was 7.4 ± 3.1 days in the 90 chil-
dren with no severe complication. The mean duration
of intravenous treatment with ampicillin was 3.3 ± 1.5
days.
Discussion
The main result of the presents t u d yw a st h a tc h i l d r e n
with CAP improved well with the recommended treat-
ment by oral amoxicillin or intravenous ampicillin [1,8].
However, starting with intravenous ampicillin, in this
study for three days in average, seemed to be a more
e f f e c t i v ep r a c t i c et h a ns t a r t ing with oral amoxicillin.
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mized clinical multicentre trial in over 1700 African,
A s i a no rS o u t h - A m e r i c a nc h i l d r e nh o s p i t a l i z e df o r
severe CAP, showing an equivalent effect for oral amox-
icillin and parenteral penicillin [15]. However, the cases
with fever continuing for >48 hours were rather com-
mon (19%) in both groups. Instead, our observations are
in line with the experiences from UK and Finland
[4,6,16], where the treatment is often started with intra-
venous G-penicillin for an average period of one to
three days, and then switched to oral amoxicillin. In
these studies, over 90% of the children with CAP
improved and were non-feverish within 48 hours,
usually between 12 and 24 hours after the first dose of
antibiotics [4,6]. The most recent equivalence study
from UK, however, showed that oral amoxicillin and
intravenous penicillin were equally effective in 246 chil-
dren with CAP [17]. In the present study, all patients
improved, and delayed improvement assessed by fever
still present at 48 hours was low (<5%). In fact, as many
as 75% of the patients were non-feverish as early as
24 hours after starting therapy.
Half of the 6 children with delayed decrease of fever
had atypical bacterial etiology of infection, in line with
Table 1 Duration of fever in 94 children with community-acquired pneumonia, in relation to fever and other clinical
signs/symptoms on admission, findings in physical and radiological examination and four serum non-specific
inflammatory markers
< 12 hours 12-24 hours > 24 hours p-value
(N = 27) (N = 42) (N = 25)
Fever (°C) 38.6 ± 1.3 38.7 ± 0.9 38.6 ± 0.9 0.86 §
Fever >37,5°C (N = 81) 21 (25.9) 39 (48.2) 21 (25.9) 0.19 #
Fever >39,5°C (N = 16) 7 (43.8) 7 (43.8) 2 (12.5) 0.23 #
Cough (N = 84) 26 (31.0) 36 (42.9) 22 (26.2) 0.39 #
Vomiting (N = 29) 8 (27.6) 12 (41.4) 9 (31.0) 0.81 #
Chest pain (N = 15) 3 (20.0) 8 (53.3) 4 (26.7) 0.72 #
Abdominal pain (N = 23) 6 (26.1) 11 (47.8) 6 (26.1) 0.95 #
Respiratory rate * 40.45 ± 11.7 37.5 ± 14.5 30.1 ± 12.5 0.04 §
Tachypnea † (N = 29) 10 (34.5) 15 (51.7) 4 (13.8) 0.31 #
Crackles ‡ (N = 47) 15 (31.9) 20 (42.6) 12 (25.5) 0.83 #
Dullness (N = 11) 2 (18.2) 7 (63.6) 2 (18.2) 0.37 #
Decreased breath sounds (N = 56) 13 (23.2) 27 (48.2) 17 (30.4) 0.16 #
Alveolar infiltration (N = 58) 18 (31.5) 26 (44.8) 14 (24.1) 0.19 #
Pleural fluid (N = 12) 5 (41.7) 4 (33.3) 3 (25.0) 0.74 #
CRP (mg/L) 146.2 ± 131.9 159.3 ± 118.0 102.1 ± 103.3 0.25 §
PCT (ng/mL) 14.1 ± 19.6 10.5 ± 12.9 5.9 ± 14.9 0.18 §
WBC (cells/μL) 20363 ± 9846 18343 ± 9148 15669 ± 6612 0.16 §
ESR (mm/h) 81.9 ± 29.3 68.5 ± 31.6 57.6 ± 33.9 0.03 §
Data are presented as means ± SD or number (percentage). * Data were missing for 18 children; † by age-specific WHO criteria; ‡ fine and medium-sized
inspiratory crackles (or rales) included. CRP: C-reactive protein; PCT: procalcitonin; WBC: white blood cells; ESR: erythrocyte sedimentation rate.
§ Analysis of variance; # Fisher’s exact test.
Table 2 Duration of fever in relation to antibiotic treatment (amoxicillin vs. ampicillin) and treatment setting
(inpatients vs. outpatients)
Amoxicillin Ampicillin p-value Inpatients Outpatients p-value
(N = 59)* (N = 21) (N = 25) (N = 69)
Hours (h) of fever 25.2 ± 18.6 13.4 ± 11.3 0.012 15.3 ± 13.6 25.8 ± 20.3 0.0056
<12 h 11 (18.6) 13 (61.9) 14 (56.0) 13 (18.8)
12-24 h 29 (49.5) 7 (33.3) <0.0001† 9 (36.0) 33 (47.8) 0.0012§
>24 h 19 (32.2) 1 (4.8) 2 (8.0) 23 (33.3)
Data are presented as means ± SD or number (percentage).
Amoxicillin was administered orally, ampicillin intravenously.
* Four children with oral amoxicillin-clavulanic acid included.
† Age-adjusted comparison between ampicillin and amoxicillin groups: p = 0.0006; age-looking-setting-adjusted comparison between ampicillin and amoxicillin
groups: p = 0.0018.
§ Age-adjusted comparison between inpatient and outpatient groups: p = 0.0058.
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dren had serological evidence of atypical bacterial etiol-
ogy, and they improved well with no treatment with
macrolides or quinolones. On the other hand, inap-
propriate selection of first line antibiotic may be the rea-
son why, in the present study, the mean duration of
fever was significantly higher in ≥5 years old children
with high rates of atypical bacterial etiology and treated
with macrolides, doxicycline or quinolones according to
most guidelines [1,8]. However, delayed recovery was in
no case due to viral infection, refractory to antibiotics,
though viral involvement was demonstrated in >40% of
the cases. Empyema needing surgical intervention was
diagnosed in two children and pulmonary abscess trea-
ted conservatively in one child. Pleural fluid was present
in one child with pneumococcal pneumonia, but
S. pneumoniae was not serologically found in the two
children with empyema. Thus, the rate of severe compli-
cations (3%) was low, in accordance with recent obser-
vations from Finland [6]. On the other hand, empyema
and other complications after childhood pneumonia
have been on increase in recent years in many countries
[5,6]. The occurrence of severe complications in chil-
dren with no underlying illness, although rare, stress the
importance to make sure that substantial improvement
of pneumonia starts within 48 hours by selected antibio-
tics [8].
We were not able to find, on admission, any useful
clinical, radiological or laboratory factor in predicting
delayed recovery or development of complications or,
on the other hand, the recovery at the situation
in which the treatment is selected appropriately. If
non-beneficial outcomes are rare, as was the case in the
present prospective study focusing on a wide severity
spectrum of CAP, retrospective case-control studies
have more statistical power. In a recent case-control
study from Finland, duration of fever before admission,
tachypnea on admission and pain on abdominal palpa-
tion were significant and independent risk factors in
multivariate analyses for empyema in children with pre-
sumptive bacterial etiology of pneumonia [6]. In the pre-
sent study, abdominal symptoms and tachypnea or
dyspnea were common, but not predictive for delayed
recovery, assessed by duration of fever. In the Finnish
study, prolonged fever and persistence of high serum
CRP during hospitalization were associated with the
development of empyema [6]. In line, CRP was elevated
in all our 6 CAP patients with delayed recovery.
Pneumococcal penicillin-resistance is rare, about 5%,
in North Italy, but pneumococcal macrolide-resistance
is as common as 25%; the figures are based on the mon-
itoring of bacterial resistance to antibiotics in clinical
samples (>600 samples from the Friuli Venezia Giulia
region in 2004-2006). The Prospective Resistant Organ-
ism Tracking and Epidemiology for the Ketolide Teli-
thromycin (PROTEKT) study [20] showed that about
40% of S. pneumoniae display multidrug-resistant phe-
notypes (resistance to three or more antibiotics), with
highly variable prevalence rates observed in different
countries; in particular, penicillin non-susceptibility and
erythromycin resistance were 35.7% and 36.0%, respec-
t i v e l y .C u r r e n t l y ,n ou s e f u la n dr a p i dt e s t sf o rp n e u m o -
coccal infection are available for children in clinical
practice. Determination of pneumococcal antigens in
Table 3 Clinical characteristics and outcome of the six children with community-acquired pneumonia and delayed
recovery
Findings Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
On admission
Age (yrs), gender 10, girls 10, boy 7, boy 8, girl 3, girl 3, girl
Fever (°C) 37.5 39.5 39.2 39.5 37.5 40.3
Looking ill no Yes yes no yes yes
CRP (mg/L) 98 270 292 82 202 426
PCT (ng/mL) 0.20 0.54 33.8 0.40 18.4 33.0
WBC (cells/μL) 8.760 18200 31400 16250 27010 31400
ESR (mm/h) 26 132 70 6 94 95
Pneumonia interstitial alveolar alveolar interstitial alveolar alveolar
Primary antibiotics macrolide vancomycin ampicillin amoxicillin ampicillin ampicillin
In hospital
Complications pleural fluid lung abscess no no empyema empyema
Fever >48 hours yes yes yes yes no no
Hospital stay no 7 days 7 days no 15 days 15 days
Serology Mycoplasma none pneumococcus mixed* mixed† none‡
* Parainfluenza viral, mycoplasmal and pneumococcal serology positive; † influenza A viral and mycoplasmal serology positive; ‡ Group A hemolytic streptococci
grew in pleural fluid.
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not been sufficiently sensitive and specific for clinical
use in children with low rate of bacteremic pneumonia
and high rate of pneumococcal carriage in nasopharynx
[21]. In addition, mixed viral-pneumococcal infections
and mixed mycoplasmal-pneumococcal infections
are common, and co-infections with S. pneumoniae are
difficult to diagnose [22].
In the present paper the diagnosis of pneumonia was
radiologically confirmed in all cases, a large microbiologi-
cal test panel was used, and patients represented the
whole spectrum of pediatric CAP. The great diversity of
etiologic agents in pediatric CAP makes the identification
of risk factors difficult, which may result in one antibiotic
(i.e. ampicillin) appearing more effective than another
(i.e. amoxicillin). For example, children who are treated
for pneumonia due to an atypical or viral infection by an
ineffective empiric agent such as a beta-lactam, more
likely will fail to improve within 48 hours, because of less
effective therapy, not because of the agent itself. As
described by Marchant et al. [23], this is a major con-
founder in clinical drug treatment and intervention trials.
Conclusions
In conclusion, respiratory rate and erythrocyte sedimen-
tation rates were associated with rapid decrease of fever,
but none of the reported signs, symptoms, radiological or
laboratory markers was able to predict delayed recovery
or development of complications in children with CAP.
According to current recommendations, S. pneumoniae
should be always covered in the treatment of CAP in
children, even in the case of proven viral or atypical bac-
terial pneumonia, as was done in >95% of the cases of the
present study. An intravenous induction of antibiotics
seemed to increase the efficacy of therapy, though the
patients treated intravenously were selected on clinical
grounds, and thus they were more severely ill [8].
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